All analyses
AI analysis

Lanka Hospitals Corp. Plc: research report

Moderately undervaluedneutralNov 13, 2026

The evidence is balanced: a 66/100 value score and cheaper-than-usual earnings multiple support LHCL, but operating profit fell 10.8% while reported profit rose. The profit uplift came largely from below operating income.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why balanced

  • It scores 66 of 100 on price against book value, earnings and dividends, placing it in the moderately undervalued band.
  • The share trades at 10.5 times trailing earnings, cheaper than 79% of days since March 2012.
  • June revenue grew 7.0% year-on-year and gross margin widened to 44.1%, showing continued top-line growth and stronger direct service profitability.

Against this. A LKR 318.5 million gain below operating profit converted a 10.8% fall in operating profit into 60.2% net profit growth.

Operating margin
18.0%
from 12.1% a year earlier
Net margin
14.4%sector 13.0%
from 11.5% a year earlier, revenue +16.8%
Return on equity
15.2%
twelve months to Sep 30, 2026, unaudited
P/E
12.2sector 11.8
earnings Rs 8.69 per share, year to Dec 2025
P/B
1.40sector 1.36
book Rs 75.90 per share
Dividend yield
2.82%sector 0.00%
34.5% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 13, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Lanka Hospitals operates a multi-speciality tertiary hospital, diagnostics, pharmacy and related healthcare services in Sri Lanka. The latest June quarter combined higher revenue and a stronger gross margin with weaker operating profit, while a substantial gain outside core operations lifted reported earnings.

Price performance

At LKR 112 on 12 November 2026, LHCL gained 6.4% in a week against a 4.9% ASPI gain, but fell 0.7% over a month while the index rose 11.9%. The recent relative weakness therefore extends beyond a single trading session.

The price sits 50.9% through its 52-week range, while 60-day volatility was 6.8% below its own one-year norm, indicating a quieter recent trading pattern. The three-year record contains one fall of 15% or more, the deepest 47%, which has not yet recovered. Liquidity is limited: median daily turnover was LKR 0.9 million, and a LKR 1 million order is more than everything that trades on a typical day (111% of it).

Valuation

At 10.5 times trailing earnings, LHCL costs about LKR 10.5 for every LKR 1 of the last twelve months' profit, below the healthcare peer median of 11.2 times. Its 1.52 times P/B means LKR 1.52 paid for each LKR 1 of net assets, modestly above the sector median of 1.40; trailing ROE of 14.6% provides some basis for that book-value premium.

The 2.7% dividend yield exceeds the sector median of 1.7%, and the payout rose to LKR 3.00 in FY2025 from LKR 1.50 in each of FY2024 and FY2023. Against its own record, the P/E is cheaper than 79% of days since March 2012 and P/B is cheaper than 61% of days since March 2012. A buyer at this price relies partly on the June quarter, which supplied 29.8% of trailing EPS; at its year-ago net margin, the same price would represent 11.6 times earnings rather than 10.5 times.

News and sentiment

There were no material company articles in the last 90 days, despite normal direct coverage. Routine disclosures included a chairman position change reported on 24 July and the FY2025 final dividend of LKR 1.00, whose ex-date was 3 June 2026, so a buyer today does not receive it.

Financials

For the June 2026 quarter, revenue rose 7.0% year-on-year to LKR 3.8 billion, but operating profit fell 10.8% to LKR 399 million. Gross margin improved from 42.9% to 44.1%, operating margin fell from 12.5% to 10.4%, and net margin rose from 12.5% to 18.8%. The gross and operating margins were middling among the last seven June quarters, while the net margin ranked second of seven.

Net profit increased 60.2% to LKR 717 million, but this did not come from the operating line. A LKR 318.5 million net gain below operating profit, covering items such as finance costs, tax, associates and foreign exchange, more than offset the decline in core profit. The profit a share is a claim on was therefore stronger in reported terms, but less clearly supported by hospital operations.

Equity increased to LKR 16.4 billion from LKR 14.6 billion a year earlier, with 223.7 million shares outstanding in both periods. These June figures are historical as at 13 November 2026 because the September interim filing is already due.

Risks

The largest risk is earnings quality: operating margin contracted by 2.1 percentage points even as net profit climbed, because below-operating items added LKR 318.5 million. If that contribution is not repeated, reported earnings would more closely reflect the weaker operating result.

Balance-sheet liquidity was strong at the latest audited year-end. The current ratio was 4.15 times, meaning LKR 4.15 of assets expected to turn into cash within a year, including inventories and customer balances, for every LKR 1 of bills due in that year. Interest cover was 36.0 times, meaning operating profit covered the interest bill many times over, and cash conversion was 1.26 times, so audited operating profit was backed by operating cash flow. Trading liquidity remains a practical risk, with a LKR 1 million order exceeding a typical day's turnover.

Outlook

As at 13 November 2026, the next specific catalyst is the September 2026 interim filing, which is due now and was expected between 5 and 14 November. It will show whether the June operating-profit decline was temporary or whether reported earnings continue to depend on gains outside hospital operations. The available data cannot establish the source or repeatability of those below-operating gains.

About this report. Generated on Nov 13, 2026 from market data up to Nov 12, 2026, 0 material news articles over 90 days and financials to Jun 30, 2026, and scored 66 of 100 on value (moderately undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports